Dr. Wirth on Takeaways From the SELECT Trial in Thyroid Cancer
August 31st 2018Lori J. Wirth, MD, associate professor of medicine, Harvard Medical School, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, discusses takeaways from the SELECT trial in patients with thyroid cancer.
Read More
Dr. Wirth on the Use of Lenvatinib in Hypertensive Patients With Thyroid Cancer
June 18th 2018Lori J. Wirth, MD, associate professor, Medicine, Harvard Medical School, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, discusses the use of lenvatinib in hypertensive patients with thyroid cancer.
Read More
Dr. Wirth Discusses the Safety Profile of Lenvatinib as Seen in the SELECT Trial
July 15th 2014Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses the safety profile of lenvatinib as seen in the phase III SELECT trial, which analyzed lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer.
Read More